Dual mechanism inhibitors for the treatment of disease
View Patent ↗Provided are compounds that are inhibitors of both rho kinase and of a monoamine transporter (MAT) act to improve the disease state or condition. Further provided are compositions comprising the compounds. Further provided are methods for treating diseases or conditions, the methods comprising administering compounds according to the invention. One such disease may be glaucoma for which, among other beneficial effects, a marked reduction in intraocular pressure (IOP) may be achieved.
1. A compound according to Formula II:
and salts thereof,
wherein R 1 and R 2 are independently hydrogen, C 1 -C 4 alkyl, aryl, C 1 -C 4 alkyl aryl, C 1 -C 4 alkyl heteroaryl, C 1 -C 4 alkyl heterocyclyl, C 2 -C 4 alkenyl, C 2 -C 4 alkynyl, C 1 -C 4 carbonyl, C 1 -C 4 carbonylamino, C 1 -C 4 alkoxy, C 1 -C 4 sulfonyl, C 1 -C 4 sulfonylamino, C 1 -C 4 thioalkyl, C 1 -C 4 carboxyl, or form a ring with each other or with A;
wherein R 3 is hydrogen;
wherein A is C 1 -C 4 alkyl;
wherein B is hydrogen, an aryl group, a heteroaryl group, a cycloalkyl group, a heterocycloalkyl group, C 1 -C 22 alkyl, C 1 -C 22 alkyl aryl, C 1 -C 22 alkyl heteroaryl, C 2 -C 22 alkenyl, C 2 -C 22 alkynyl, C 1 -C 22 carbonyl, C 1 -C 22 carbonylamino, C 1 -C 22 alkoxy, C 1 -C 22 sulfonyl, C 1 -C 22 sulfonylamino, C 1 -C 22 thioalkyl, or C 1 -C 22 carboxyl;
wherein X 1 , X 2 , and X 3 are, independently, hydrogen, halogen, or C 1 -C 4 alkyl;
wherein the double circle indicates a phenyl ring; and
wherein each Z is independently a bond or C 1 -C 4 alkyl.
2. A compound according to claim 1 , wherein R 1 is hydrogen or C 1 -C 4 alkyl; B is C 1 -C 22 carbonyl; and X 1 , X 2 , and X 3 are hydrogen.
3. A compound according to claim 1 , wherein Z is a bond or —CH 2 —.
4. A compound according to claim 1 , wherein X 1 , X 2 and X 3 are each hydrogen.
5. A compound according to claim 1 , wherein A is —CH 2 CH 2 —.
6. A compound according to claim 1 , wherein R 1 and R 2 are independently hydrogen or methyl.
7. A pharmaceutical composition comprising a compound according to claim 1 and a pharmaceutically acceptable carrier.
8. A method for treating a disease in a subject comprising:
administering to a subject an effective amount of a compound according to claim 1 ;
wherein the disease comprises glaucoma or dry eye.
9. The method of claim 8 , wherein intraocular pressure is reduced.
10. A method of modulating kinase activity comprising:
contacting a cell with a compound according to claim 1 in an amount effective to modulate kinase activity.
11. The method of claim 10 , wherein the cell is in a subject.
12. A method of reducing intraocular pressure in a patient in need using:
a compound according to claim 1 .